Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer.

Clin Pract · 2021 · PMC8293071 · PMID 34287275

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with any positive autoimmune antibody (antiSOX2, anti-Hu, anti-Yo, anti-VGCCA, anti-VGPCA, antinuclear, or anti-neutrophil cytoplasmic antibodies) showed a trend for prolonged survival and better PFS in a study combining carboplatin plus etoposide with ipilimumab [ 36 ], but this assessment has not been included in other studies to explore its potential as a biomarker further.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.